Stanford-StartX Fund-backed TwoXar has added $10m in funding to its coffers thanks to SoftBank Ventures, Andreessen Horowitz and OS Fund.

TwoXar, a US-based biopharmaceutical company backed by university venture fund Stanford-Start X Fund, secured $10m in series A capital yesterday from investors led by SoftBank Ventures, the early-stage investment arm of telecoms group SoftBank.

VC firm Andreessen Horowitz, through its Bio Fund, and venture capital vehicle OS Fund also contributed to the round.

Founded in 2014, TwoXar has developed a drug discovery platform that relies on artificial intelligence (AI) technology to reduce the time it takes to identify candidates from…